CompletedNCT00640601
Long-term quetiapine XR for clinical improvement in schizophrenia
About this title
Read the official source — NCT00640601Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Garran and 35 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 331
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Australia, Canada, China, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00640601
- Official title
Show the full official title
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Garran, Australia · Newcastle, Australia · Brisbane, Australia
34 more locations
- Meadowbrook, Australia
- Dandenong, Australia
- Calgary, Canada
- Claresholm, Canada
- Red Deer, Canada
- Vancouver, Canada
- Victoria, Canada
- Miramichi, Canada
- St. John's, Canada
- Sydney, Canada
- Belleville, Canada
- Brantford, Canada
- Chatham, Canada
- Cornwall, Canada
- Greater Sudbury, Canada
- London, Canada
- Markham, Canada
- Mississauga, Canada
- Newmarket, Canada
- Oakville, Canada
- Orléans, Canada
- Toronto, Canada
- Windsor, Canada
- Gatineau, Canada
- Greenfield Park, Canada
- Montreal, Canada
- Québec, Canada
- Rouyn-Noranda, Canada
- Verdun, Canada
- Prince Albert, Canada
- Saskatoon, Canada
- Hong Kong, Hong Kong
- Seoul, South Korea
- China
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine Fumarate Extended- Release.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
